查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933892

按產品類型、技術、樣本類型、最終用戶和應用分類的即時血液檢測產品市場—全球預測，2026-2032年

Point of Care Blood Testing Product Market by Product Type, Technology, Sample Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，照護現場血液檢測產品市場規模將達到 198.2 億美元，到 2026 年將成長至 212.9 億美元，複合年成長率為 8.24%，到 2032 年將達到 345.1 億美元。

關鍵市場統計數據
基準年 2025 198.2億美元
預計年份：2026年 212.9億美元
預測年份 2032 345.1億美元
複合年成長率 (%) 8.24%

本文簡要概述了分散式診斷以及影響照護現場血液檢測普及的關鍵臨床、技術和營運趨勢。

照護現場血液檢測正在迅速改變臨床工作流程，使診斷不再局限於傳統檢查室，並能在各種醫療環境中加快臨床決策。本報告首先概述了當前形勢，說明了設備小型化、互聯互通和監管協調如何降低了從急診到居家照護等各個領域的應用門檻。引言部分為製造商、醫療系統和醫保報銷相關人員最為關注的技術和應用案例構建了框架，並明確了構成後續分析基礎的核心術語和設備類別。

技術創新、不斷變化的法規以及以價值為導向的醫療模式正在從根本上重新定義施行地點。

照護現場血液檢測領域正經歷著變革性的轉變，這主要得益於技術創新、法規的不斷改進以及醫療服務模式的轉變。分子診斷和免疫檢測靈敏度的提高，拓展了可在床邊可靠檢測的分析物範圍；同時，電化學和光學感測器技術的進步降低了檢測的複雜性和成本。這些創新使得以往需要中心檢查室才能完成的疾病檢測成為可能，有助於在各種醫療環境中更快地做出臨床決策、進行分診和治療。

針對美國不斷增加的關稅壓力對診斷零件和組件的影響，製造業、採購和購買環節的營運和戰略應對措施

2025年美國關稅政策的實施推高了照護現場血液檢測所需某些零件和成品設備的投入成本，促使製造商和經銷商重新評估其採購和定價策略。供應鏈管理人員已採取應對措施，包括供應商多元化、增加本地庫存緩衝以及加快關鍵零件的近岸外包，以降低進口關稅風險。這些營運調整對前置作業時間和採購複雜性產生了顯著影響，尤其對於那些依賴專用試劑和精密設計的感測器組件的設備而言更是如此。

透過對產品分類、臨床環境、臨床應用、平台技術和檢體類型進行詳細的細分分析，確定產品推廣促進因素和發展重點。

細分市場分析揭示了臨床需求、技術能力和商業性機會在產品類型、最終用戶、應用、技術和檢體類型方面的契合點。產品層面的差異化主要體現在檢測方式：血液氣體分析、心臟標記、血液凝固檢驗、血糖監測、血紅素/血液學、傳染病檢查。血液凝固檢驗進一步細分為APTT、D-二聚體和PT/INR檢測，而傳染病檢查則涵蓋COVID-19、肝炎、HIV和流感。能夠在照護端進行多種互補檢測的設備，透過減少檢體處理和縮短診斷時間，確保了其顯著的臨床效用。最終用戶涵蓋門診中心、診斷檢查室、居家醫療機構、醫院和診所，每種機構的採用促進因素各不相同，包括檢測量和結果週轉時間、人員配備和報銷問題等。醫院優先考慮設備的穩定性和整合性，而居家醫療機構則更注重易用性和連接性。

區域比較：醫療保健系統和法規環境的差異如何影響採納路徑和打入市場策略

區域分析表明，醫療基礎設施、法規結構和推廣路徑的差異正在影響照護現場血液檢測的普及。美洲地區在急診和基層醫療機構中正迅速普及即時血液檢測，這得益於其整合的醫療網路和獎勵縮短住院時間和改善慢性病管理的報銷體系。同時，歐洲、中東和非洲的情況則更為複雜。在這些地區，監管協調正在加速部分國家的普及，而資源匱乏的國家則更需要成本更低、功能更強大的平台和分散式檢查策略。此外，亞太地區正經歷著用於提升診斷能力的公私投資快速成長，這主要受目標疾病高發生率以及政府為擴大偏遠和都市化地區檢測覆蓋範圍而採取的舉措的推動。

競爭格局分析強調臨床檢驗、互通性和策略合作夥伴關係是照護現場設備製造商的關鍵差異化因素。

照護現場血液檢測領域的競爭格局由成熟的診斷設備製造商、專業設備創新者和尋求佔據特定臨床適應症的新興技術參與企業組成。擁有深厚的臨床檢驗、豐富的監管經驗和規模化生產能力的公司在醫院和檢查室管道保持優勢，而規模較小、小規模靈活的公司則往往在用戶界面設計、試劑化學和分子檢測小型化方面引領創新。策略差異化越來越依賴將設備整合到臨床工作流程中的能力，這需要透過軟體、連接性和決策支援功能，為臨床醫生提供超越原始數據分析效能的實際價值。

為開發人員和商業領導者提供切實可行的策略藍圖，以加速臨床應用、降低供應風險並確保永續的競爭優勢。

產業領導者應採取協作策略，協調產品設計、法規事務和通路開發，以加速目標臨床機構的推廣應用。優先採用平台化方法，實現模組化檢測擴展，初期優先推出凝血監測亞型和主要傳染病檢查等高影響力檢測，隨後利用同一硬體生態系分階段推出其他檢測項目。同時，應投資改善使用者體驗和連接解決方案，確保與臨床工作流程和電子健康記錄 (EHR) 無縫整合，並降低臨床醫生採用的障礙。

我們採用了一種綜合性的混合方法研究設計，結合了與主要相關人員的直接對話、二手證據的綜合以及情景建模，以檢驗我們的實際結論。

本研究採用混合方法，結合定性一手資料收集和量化資料整合，以建立可靠的實證理解。一手研究包括對臨床醫生、檢查室管理人員、採購負責人和監管專家進行結構化訪談，以了解醫療保健機構中實際面臨的挑戰和推動技術應用的因素。系統地回顧了二手資料，以了解技術趨勢、監管更新和公共衛生因素的背景，並透過與一手研究結果的三角驗證，檢驗了新出現的主題。

一份簡明扼要的綜述，重點闡述了實現分散式血液診斷變革潛力的臨床、營運和策略要務。

照護現場血液檢測正處於轉折點，技術進步、不斷演進的醫療模式和不斷變化的監管環境正在匯聚，為改善患者療效和提升營運效率創造了切實機會。最成功的方案將結合嚴格的臨床檢驗、以使用者為中心的設計、完善的品質體係以及靈活的商業模式，以滿足包括醫院、門診中心、檢查室和居家醫療機構在內的各個場所的獨特需求。監管合規性和供應鏈韌性同樣重要，尤其是在地緣政治和關稅相關的不確定性影響組件採購和定價的時期。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的即時血液檢測產品市場

  • 血氣分析
  • 心臟標記物
  • 血液凝固檢驗
    • APTT 試驗
    • D-二聚體檢測
    • PT INR 檢測
  • 血糖監測
  • 血紅素和血液學
  • 傳染病檢查
    • 新型冠狀病毒感染疾病（COVID-19）
    • 肝炎
    • HIV
    • 流感

9. 按技術分類的即時血液檢測產品市場

  • 電化學
  • 免疫檢測
  • 分子診斷
  • 光學

10. 依檢體類型分類的即時血液檢測產品市場

  • 微血管血
  • 電漿
  • 血清
  • 靜脈血
  • 全血

第11章：以最終用戶分類的即時血液檢測產品市場

  • 門診治療中心
  • 診斷檢查室
  • 居家醫療環境
  • 醫院
  • 醫生診所

第12章：按應用分類的即時血液檢測產品市場

  • 心電圖監測
  • 凝血監測
  • 重症監護
  • 糖尿病監測
  • 感染疾病診斷

13. 按地區分類的即時血液檢測產品市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 依組別分類的即時血液檢測產品市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國即時血液檢測產品市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國即時血液檢測產品市場

第17章：中國即時血液檢測產品市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abaxis
  • Abbott Laboratories
  • Accriva Diagnostics
  • ACON Laboratories
  • ARKRAY, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • HemoCue
  • Instrumentation Laboratory
  • Meridian Bioscience
  • Nova Biomedical Corporation
  • Ortho Clinical Diagnostics
  • PTS Diagnostics
  • QuidelOrtho Corporation
  • Roche Diagnostics International AG
  • Sekisui Diagnostics
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Trinity Biotech
  • Werfen
Product Code: MRR-C36616F699AA

The Point of Care Blood Testing Product Market was valued at USD 19.82 billion in 2025 and is projected to grow to USD 21.29 billion in 2026, with a CAGR of 8.24%, reaching USD 34.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.82 billion
Estimated Year [2026] USD 21.29 billion
Forecast Year [2032] USD 34.51 billion
CAGR (%) 8.24%

A concise orientation to decentralized diagnostics and the defining clinical, technological, and operational trends that shape point-of-care blood testing adoption

Point-of-care blood testing is rapidly reshaping clinical workflows, extending diagnostics beyond traditional laboratories and enabling faster clinical decision-making across diverse care settings. This report opens with an orientation to the current landscape, emphasizing how device miniaturization, connectivity, and regulatory harmonization have collectively reduced barriers to deployment in settings ranging from emergency departments to home-based care. The introduction frames the technologies and use cases that are most consequential for manufacturers, health systems, and reimbursement stakeholders, while clarifying core terminology and device classes that underpin subsequent analysis.

The narrative situates point-of-care blood testing within the broader trend toward decentralized and patient-centric care. It highlights how clinical priorities-such as reducing time to diagnosis for infectious diseases, optimizing anticoagulation management through coagulation monitoring, and enabling real-time glucose and cardiac marker measurement-drive procurement and adoption decisions. Furthermore, the introduction underscores the role of interoperability, quality assurance, and clinician training in determining how quickly and effectively point-of-care tools integrate into established clinical pathways, setting the stage for deeper examination of market dynamics and strategic implications in later sections.

How technological innovation, regulatory evolution, and value-based care models are fundamentally redefining where and how blood diagnostics are performed

The landscape for point-of-care blood testing is undergoing transformative shifts driven by technological innovation, regulatory evolution, and changing care delivery models. Advances in molecular diagnostics and immunoassay sensitivity have expanded the range of analytes that can be reliably measured at the bedside, while improvements in electrochemical and optical sensor technology have lowered per-test complexity and cost. These innovations enable accurate testing for conditions that previously required centralized laboratories, thereby accelerating clinical decision-making and enabling triage and treatment in diverse settings.

Concurrently, regulatory pathways in many jurisdictions are adapting to accommodate rapid diagnostic technologies, with a focus on post-market surveillance and quality controls that maintain clinical standards while reducing time to market. The shift toward value-based care and bundled payment models incentivizes shorter hospital stays and outpatient management, underscoring the need for point-of-care tests that deliver actionable results quickly. Integration with electronic health records and cloud-based analytics is enhancing data continuity and enabling remote monitoring, which supports chronic disease management and population health initiatives. Taken together, these shifts are redefining where diagnostics occur, who performs them, and how results inform both immediate and longitudinal clinical decisions.

Operational and strategic responses across manufacturing, sourcing, and procurement to elevated United States tariff pressures affecting diagnostic components and assemblies

The tariff environment in the United States in 2025 introduced elevated input costs for certain components and finished devices used in point-of-care blood testing, prompting manufacturers and distributors to reassess sourcing and pricing strategies. Supply chain managers responded by diversifying supplier bases, increasing local inventory buffers, and accelerating nearshoring initiatives for critical components to mitigate exposure to import duties. These operational shifts had measurable downstream effects on production lead times and procurement complexity, particularly for devices that rely on specialized reagents and precision-engineered sensor components.

In response, manufacturers prioritized design-for-manufacture approaches that reduced dependence on tariff-sensitive subsystems, while commercial teams adjusted contract structures to absorb or pass through additional costs in ways that preserved adoption momentum among health systems and ambulatory care providers. Strategic partnerships and long-term supply agreements emerged as mechanisms for stabilizing unit economics and minimizing price volatility. From a clinical standpoint, buyers emphasized total cost of ownership and reliability over headline device pricing, which influenced procurement decisions in hospitals, diagnostic laboratories, and decentralized care environments. These dynamics are likely to persist as stakeholders balance cost containment with the clinical imperative for rapid, reliable point-of-care testing.

In-depth segmentation intelligence linking product classes, care settings, clinical applications, enabling technologies, and sample modalities to reveal adoption levers and development priorities

Segmentation insights reveal where clinical needs align with technological capabilities and commercial opportunity across product types, end users, applications, technologies, and sample types. Product-level differentiation centers on modalities such as Blood Gas Analysis, Cardiac Markers, Coagulation Testing, Glucose Monitoring, Hemoglobin Hematology, and Infectious Disease Testing, with coagulation further subdivided into APTT testing, D dimer testing, and PT INR testing and infectious disease assays covering Covid-19, Hepatitis, HIV, and Influenza; devices that can perform multiple complementary assays at the point of care secure distinct clinical utility by reducing sample handling and accelerating decision timelines. End users span Ambulatory Care Centers, Diagnostic Laboratories, Home Care Settings, Hospitals, and Physicians Offices, each exhibiting different adoption drivers ranging from throughput and turnaround time to staffing and reimbursement concerns; hospitals prioritize robustness and integration, while home care settings emphasize ease of use and connectivity.

Applications cluster around Cardiac Monitoring, Coagulation Monitoring, Critical Care, Diabetes Monitoring, and Infectious Disease Diagnosis, with the highest clinical urgency found where rapid intervention changes patient outcomes. Technologies such as Electrochemical sensors, Immunoassay platforms, Molecular Diagnostics, and Optical detection shape assay sensitivity, specificity, and portability, and therefore influence which applications can realistically migrate to the point of care. Sample type considerations-Capillary Blood, Plasma, Serum, Venous Blood, and Whole Blood-determine pre-analytical workflows and user training requirements; capillary and whole blood testing favor decentralized use but require rigorous quality assurance to ensure clinical concordance with laboratory standards. Cross-segmentation analysis highlights that successful offerings combine an appropriate technology for the intended analyte, a user-centric interface for the target end user, and validated workflows for the chosen sample type to achieve adoption at scale.

Comparative regional dynamics showing how divergent healthcare systems and regulatory environments influence adoption pathways and go-to-market strategies

Regional insights reflect differing healthcare infrastructures, regulatory frameworks, and adoption pathways that shape how point-of-care blood testing is deployed. The Americas continue to emphasize rapid adoption in both acute care and primary care settings, supported by integrated health networks and reimbursement mechanisms that reward reduced length of stay and improved chronic disease management. In contrast, Europe, Middle East & Africa present a heterogeneous picture where regulatory harmonization in some countries accelerates adoption while resource constraints in others concentrate demand for low-cost, ruggedized platforms and decentralized testing strategies. Meanwhile, Asia-Pacific demonstrates strong growth in private and public investments for diagnostic capacity, driven by high prevalence of target conditions and government initiatives to expand access to testing in remote and urbanizing populations.

Across regions, differences in supply chain configurations and local manufacturing capabilities influence procurement timelines and pricing. Interoperability expectations and digital health infrastructure maturity also vary, which affects the extent to which data integration and remote monitoring features are realized. Stakeholders operating across these geographies must therefore tailor go-to-market approaches to align with local reimbursement models, regulatory requirements, and clinical practice patterns while leveraging scalable technology architectures that accommodate regional customization and global quality standards.

Competitive landscape analysis emphasizing clinical validation, interoperability, and strategic partnerships as decisive differentiators for point-of-care device makers

Competitive dynamics in point-of-care blood testing are shaped by a mix of established diagnostic manufacturers, specialist device innovators, and emerging technology entrants seeking to capture niche clinical indications. Companies that combine deep clinical validation, regulatory experience, and manufacturing scale maintain advantages in hospital and laboratory channels, while smaller, agile firms frequently drive innovation in user interface design, reagent chemistry, and molecular assay miniaturization. Strategic differentiation increasingly rests on the ability to integrate devices into clinical workflows through software, connectivity, and decision-support features that deliver clear clinician value beyond raw analytical performance.

Partnerships and alliances between device makers, reagent suppliers, and software developers are becoming more prevalent as firms seek to offer turnkey solutions that address the full testing pathway from sample collection to result interpretation and data management. Intellectual property around sensor technology and assay chemistries remains a critical barrier to entry for late-stage analytes, while nimble companies with strong reimbursement strategies and targeted clinical evidence can capture early-adopter segments. Additionally, manufacturers with robust post-market surveillance and quality systems secure trust among institutional buyers, who increasingly demand longitudinal performance data and clear lifecycle management plans for point-of-care platforms.

Actionable strategic blueprint for developers and commercial leaders to accelerate clinical adoption, mitigate supply risks, and secure sustainable competitive advantage

Industry leaders should pursue a coordinated strategy that aligns product design, regulatory engagement, and channel development to accelerate adoption across targeted care settings. Prioritize platform approaches that enable modular assay expansion, permitting an initial commercial entry with high-impact tests-such as coagulation monitoring subtypes or key infectious disease assays-followed by a staged rollout of additional analytes that leverage the same hardware ecosystem. Simultaneously, invest in user experience refinements and connectivity solutions to ensure seamless integration into clinical workflows and electronic health records, thereby reducing barriers to clinician adoption.

Operationally, diversify supply chains and consider nearshoring critical component production to mitigate tariff exposure and reduce lead-time volatility. Strengthen partnerships with clinical networks and key opinion leaders to generate pragmatic, peer-reviewed evidence that demonstrates real-world clinical utility and cost-effectiveness. Finally, tailor market entry strategies to specific end users by aligning pricing and support models with the procurement realities of hospitals, ambulatory centers, diagnostic laboratories, and home care providers, and ensure training and quality control resources are available to sustain long-term utilization and trust.

Comprehensive mixed-methods research design combining primary stakeholder engagement, secondary evidence synthesis, and scenario modeling to validate actionable conclusions

This research employed a mixed-methods approach that combined primary qualitative engagement with quantitative data synthesis to ensure robust, evidence-based findings. Primary research included structured interviews with clinicians, laboratory directors, procurement leads, and regulatory experts to capture real-world operational challenges and adoption drivers across care settings. Secondary sources were systematically reviewed to contextualize technological trends, regulatory updates, and public health drivers, and were triangulated with primary inputs to validate emerging themes.

Analytical methods encompassed cross-segmentation mapping to align product attributes with end-user needs, scenario analysis to assess impacts of policy and tariff changes on sourcing strategies, and technology readiness assessments that evaluated assay performance, manufacturability, and integration potential. Data quality was reinforced through respondent verification, expert panel reviews, and iterative synthesis to ensure that conclusions reflect both empirical evidence and practical stakeholder perspectives. Ethical considerations and data governance standards guided the treatment of proprietary inputs and ensured that analytical outputs remain actionable for commercial and clinical decision-makers.

Concise synthesis highlighting clinical, operational, and strategic imperatives for realizing the transformative potential of decentralized blood diagnostics

Point-of-care blood testing stands at an inflection point where converging technological advances, evolving care models, and shifting regulatory landscapes create tangible opportunities to improve patient outcomes and operational efficiency. The most successful initiatives will be those that marry rigorous clinical validation with user-centric design, robust quality systems, and flexible commercial models that address the distinct needs of hospitals, ambulatory centers, laboratories, and home care settings. Regulatory navigation and supply chain resilience are equally critical, particularly in the context of geopolitical and tariff-driven uncertainties that affect component sourcing and pricing.

As stakeholders evaluate investment and partnership opportunities, they should prioritize solutions that demonstrate clear clinical utility, interoperability, and total cost implications within real-world care pathways. By focusing on modular platforms, targeted assay portfolios, and scalable distribution strategies, manufacturers and health systems can accelerate deployment while maintaining the quality and reliability that clinicians expect. The cumulative effect will be a more distributed diagnostic ecosystem that supports faster clinical decisions, better chronic disease management, and more resilient healthcare delivery models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point of Care Blood Testing Product Market, by Product Type

  • 8.1. Blood Gas Analysis
  • 8.2. Cardiac Markers
  • 8.3. Coagulation Testing
    • 8.3.1. APTT Testing
    • 8.3.2. D Dimer Testing
    • 8.3.3. PT INR Testing
  • 8.4. Glucose Monitoring
  • 8.5. Hemoglobin Hematology
  • 8.6. Infectious Disease Testing
    • 8.6.1. Covid-19
    • 8.6.2. Hepatitis
    • 8.6.3. HIV
    • 8.6.4. Influenza

9. Point of Care Blood Testing Product Market, by Technology

  • 9.1. Electrochemical
  • 9.2. Immunoassay
  • 9.3. Molecular Diagnostics
  • 9.4. Optical

10. Point of Care Blood Testing Product Market, by Sample Type

  • 10.1. Capillary Blood
  • 10.2. Plasma
  • 10.3. Serum
  • 10.4. Venous Blood
  • 10.5. Whole Blood

11. Point of Care Blood Testing Product Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Home Care Settings
  • 11.4. Hospitals
  • 11.5. Physicians Offices

12. Point of Care Blood Testing Product Market, by Application

  • 12.1. Cardiac Monitoring
  • 12.2. Coagulation Monitoring
  • 12.3. Critical Care
  • 12.4. Diabetes Monitoring
  • 12.5. Infectious Disease Diagnosis

13. Point of Care Blood Testing Product Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Point of Care Blood Testing Product Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Point of Care Blood Testing Product Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Point of Care Blood Testing Product Market

17. China Point of Care Blood Testing Product Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abaxis
  • 18.6. Abbott Laboratories
  • 18.7. Accriva Diagnostics
  • 18.8. ACON Laboratories
  • 18.9. ARKRAY, Inc.
  • 18.10. Beckman Coulter
  • 18.11. Becton, Dickinson and Company
  • 18.12. bioMerieux SA
  • 18.13. Bio-Rad Laboratories
  • 18.14. Chembio Diagnostics
  • 18.15. Danaher Corporation
  • 18.16. EKF Diagnostics Holdings plc
  • 18.17. HemoCue
  • 18.18. Instrumentation Laboratory
  • 18.19. Meridian Bioscience
  • 18.20. Nova Biomedical Corporation
  • 18.21. Ortho Clinical Diagnostics
  • 18.22. PTS Diagnostics
  • 18.23. QuidelOrtho Corporation
  • 18.24. Roche Diagnostics International AG
  • 18.25. Sekisui Diagnostics
  • 18.26. Siemens Healthineers AG
  • 18.27. Sysmex Corporation
  • 18.28. Thermo Fisher Scientific
  • 18.29. Trinity Biotech
  • 18.30. Werfen

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY BLOOD GAS ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY BLOOD GAS ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY BLOOD GAS ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APTT TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APTT TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APTT TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY D DIMER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY D DIMER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY D DIMER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PT INR TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PT INR TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PT INR TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEMOGLOBIN HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEMOGLOBIN HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEMOGLOBIN HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY OPTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY OPTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY OPTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CAPILLARY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CAPILLARY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY VENOUS BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY VENOUS BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 182. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 183. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 206. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 207. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)